Traditional Chinese medicine composition for relieving liver depression and qi stagnation syndrome type depression
Through a composition composed of traditional Chinese medicine, the problem of adverse reactions of antidepressants is solved by targeting depression, qi stagnation syndrome, combined with the treatment principles of relieving liver qi, nourishing blood and softening liver, and significantly improving the adverse reactions of patients with depression Mental and physical symptoms, and improve immunity, achieving significant effects in combination with Western medicine.
Patent Information
- Application Number
- CN202411046112.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-12
AI Technical Summary
Existing antidepressants have adverse reactions in the treatment of liver depression and Qi stagnation syndrome, and seek alternative or supplementary means to improve treatment effectiveness and safety.
A Chinese medicine composition is adopted, which consists of tangerine peel, Bupleurum, Chuanxiong, Xiangfu, Citrus aurantium, White Peony, Roasted Licorice, Alien peel, Scutellaria baicalensis, Poria cocos, Pinellia ternata, Apricot, Forsythia, Codonopsis pilosula, and Tibetan Muxiang , beef yellow and musk are composed of, and powder is made into a specific preparation method, mixed with dextrin, sterilized and bagged, used to treat liver depression and qi stagnation syndrome.
This traditional Chinese medicine composition significantly improves the mental symptoms of depression patients, reduces body inflammatory reactions, improves immunity, reduces immunity, reduces irritability, and improves the patient by relieving the liver and regulating qi, nourishing blood, regulating blood, strengthening the spleen, calming the mind and awakening the brain. The overall function of the medicine is significantly better than that of Western medicine alone when used in combination with Western medicine.
Smart Images

Figure CN118924835A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of depression of liver depression and qi stagnation syndrome, and in particular to a traditional Chinese medicine composition for relieving depression of liver depression and qi stagnation syndrome. Background Art
[0002] Depression is a common and frequently occurring disease in psychiatric clinic, which has a serious impact on patients' work and life.
[0003] Currently, antidepressants are the main means of treating depression. However, while antidepressants are effective in relieving depressive symptoms, they inevitably have various adverse reactions. Therefore, finding other alternative or supplementary means is a current research hotspot. Summary of the invention
[0004] The purpose of the present invention is to provide a Chinese medicine composition for relieving depression of liver depression and qi stagnation syndrome, so as to solve the problem of various adverse reactions of existing antidepressant drug treatment methods.
[0005] In order to solve the above problems, the present invention provides the following technical solutions:
[0006] A traditional Chinese medicine composition for relieving depression of liver depression and qi stagnation syndrome is composed of the following components: dried tangerine peel, bupleurum, chuanxiong, cyperus rotundus, fructus aurantii, white peony root, roasted licorice, julibrissin bark, scutellaria, poria, pinellia, acanthopanax, forsythia, codonopsis, Tibetan costusroot, bezoar and musk.
[0007] In a preferred embodiment, 5-10 parts of dried tangerine peel, 8-10 parts of bupleurum, 5-10 parts of chuanxiong, 7-10 parts of cyperus rotundus, 5-10 parts of fructus aurantii, 5-10 parts of white peony root, 5-10 parts of roasted liquorice, 15-20 parts of julibrissin bark, 5-10 parts of scutellaria baicalensis, 7-12 parts of poria, 5-10 parts of pinellia, 5-10 parts of acanthopanax senticosus, 5-10 parts of forsythia, 5-10 parts of codonopsis, 2-5 parts of Tibetan costusroot, 2-5 parts of bezoar, and 2-5 parts of musk.
[0008] In a preferred embodiment, 8 parts of dried tangerine peel, 9 parts of bupleurum, 8 parts of chuanxiong, 8 parts of cyperus, 8 parts of fructus aurantii, 8 parts of white peony root, 7 parts of roasted liquorice, 18 parts of julibrissin bark, 8 parts of scutellaria, 9 parts of poria, 7 parts of pinellia, 8 parts of acanthopanax, 7 parts of forsythia, 7 parts of codonopsis, 3 parts of aucklandia, 3 parts of bezoar, and 3 parts of musk.
[0009] A method for preparing a Chinese medicine composition for relieving depression of liver depression and qi stagnation syndrome comprises:
[0010] S1, take parts by weight of dried tangerine peel, bupleurum, chuanxiong, cyperus, fructus aurantii, white peony root, licorice root, julibrissin, scutellaria, tuckahoe, pinellia, acanthopanax, forsythia, and codonopsis, wash them in clean water to remove sediment and impurities, and then filter them as a mixture for later use; take parts by weight of Tibetan wood root, bezoar, and musk, grind them into powder and mix them for later use;
[0011] S2, add twice the weight of water to the mixture, the water temperature is 30-40°C, boil over high heat for 60-150 minutes, filter and take the juice for later use;
[0012] S3, add 1.5 times the weight of water to the juice, the water temperature is 30-40°C, boil over high heat and then simmer over low heat to make a concentrated solution with one quarter of the total amount of original juice and water;
[0013] S4, after the mixed concentrated liquid is dried, a solid is obtained, the solid is ground into powder, dextrin and the powder mixture of step S1 are added, mixed, sterilized, bagged and packaged.
[0014] Compared with the prior art, the present invention has the following beneficial effects:
[0015] (1) The present invention is aimed at patients with depression of the liver depression and qi stagnation syndrome type, and the treatment is mainly based on drugs that dissipate pungent and enter the liver to regulate qi, supplemented by drugs that nourish the blood and soften the liver, promote blood circulation and soothe the stomach, soothe the liver and nourish the liver, regulate qi and regulate blood, regulate the liver and strengthen the spleen and soothe the stomach, sort out the stagnation of qi, regulate qi, so that the mental symptoms of patients with depression are improved, the patient's somatic inflammatory response is reduced, and the immunity of patients with depression is improved.
[0016] (2) The drug combination of dried tangerine peel, bupleurum, chuanxiong, cyperus, fructus aurantii, white peony root and glycyrrhiza uralensis in the present invention can soothe and nourish the liver, regulate qi and regulate blood, regulate the liver and strengthen the spleen and stomach; the drug combination of elixir bark, scutellaria, poria, pinellia, acanthopanax, forsythia and codonopsis can help the body's qi and blood biochemical, replenish qi and nourish deficiency, restore the generation and circulation of qi and blood, and achieve the effects of replenishing qi and blood, nourishing blood and calming the nerves; the drug combination of Tibetan wood root, bezoar and musk can open up the mind and refresh the nerves, calm the nerves and refresh the brain; each drug combination complements each other, and on the basis of soothing and nourishing the liver, it also replenishes the body's qi and blood, calms the nerves and refreshes the brain. The treatment of soothing and nourishing the liver relieves liver depression and qi stagnation syndrome, and the treatment effect of soothing and nourishing the liver is better by replenishing qi and blood, nourishing blood and calming the nerves. On the basis of replenishing qi and blood, nourishing blood and calming the nerves, it calms the nerves and refreshes the brain, reduces irritability and boredom, makes the patient's mentality more peaceful, and improves the patient's own function as a whole. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 This is a flow chart of Example 1. DETAILED DESCRIPTION
[0018] The present invention is further described below in conjunction with the accompanying drawings and examples. The embodiments of the present invention include but are not limited to the following examples.
[0019] Depression is a very common mental illness in clinical practice, which is called "depression" in traditional Chinese medicine. Since ancient times, traditional Chinese medicine has accumulated rich theories and treatment experience. Liver depression and qi stagnation, and mental disorder are the basic pathogenesis of depression in traditional Chinese medicine. The treatment should focus on soothing the liver and regulating qi, and regulating emotions. Traditional Chinese medicine can play a role in the treatment of depression throughout the course of the disease: intervene in the disease in the early stage of the disease to prevent the development and change of the disease; relieve symptoms and reduce adverse drug reactions in the acute stage of the disease; provide assistance in the consolidation and maintenance stages of the disease to help patients go through the stage of reducing and withdrawing medication until they stop taking the medication smoothly; the following examples illustrate this.
[0020] Example 1
[0021] A traditional Chinese medicine composition for relieving depression of liver depression and qi stagnation syndrome consists of the following components: 5 parts of dried tangerine peel, 8 parts of bupleurum, 5 parts of chuanxiong, 7 parts of cyperus rotundus, 5 parts of fructus aurantii, 5 parts of white peony root, 5 parts of roasted liquorice, 15 parts of julibrissin bark, 5 parts of scutellaria baicalensis, 7 parts of poria, 5 parts of pinellia, 5 parts of acanthopanax senticosus, 5 parts of forsythia, 5 parts of codonopsis, 2 parts of Tibetan costusroot, 2 parts of bezoar and 2 parts of musk.
[0022] A method for preparing a Chinese medicine composition for relieving depression of liver depression and qi stagnation syndrome comprises:
[0023] S1, take parts by weight of dried tangerine peel, bupleurum, chuanxiong, cyperus, fructus aurantii, white peony root, licorice root, julibrissin, scutellaria, tuckahoe, pinellia, acanthopanax, forsythia, and codonopsis, wash them in clean water to remove sediment and impurities, and then filter them as a mixture for later use; take parts by weight of Tibetan wood root, bezoar, and musk, grind them into powder and mix them for later use;
[0024] S2, add twice the weight of water to the mixture, the water temperature is 30°C, boil over high heat for 60-150 minutes, filter and take the juice for later use;
[0025] S3, add 1.5 times the weight of water to the juice, the water temperature is 30°C, boil over high heat and then simmer over low heat until the original juice and water are concentrated to a quarter of the total amount;
[0026] S4, after the mixed concentrated liquid is dried, a solid is obtained, the solid is ground into powder, dextrin and the powder mixture of step S1 are added, mixed, sterilized, bagged and packaged.
[0027] Example 2
[0028] The difference between this embodiment and embodiment 1 is that 8 parts of dried tangerine peel, 9 parts of bupleurum, 8 parts of chuanxiong, 8 parts of cyperus, 8 parts of aurantium, 8 parts of white peony root, 7 parts of roasted liquorice, 18 parts of julibrissin bark, 8 parts of scutellaria, 9 parts of poria, 7 parts of pinellia, 8 parts of acanthopanax, 7 parts of forsythia, 7 parts of codonopsis, 3 parts of aucklandia, 3 parts of bezoar, and 3 parts of musk; the temperature of water in steps S2 and S3 is 35°.
[0029] Example 3
[0030] The difference between this embodiment and embodiment 1 is that there are 10 parts of dried tangerine peel, 10 parts of bupleurum, 10 parts of chuanxiong, 10 parts of cyperus, 10 parts of aurantium, 10 parts of white peony root, 10 parts of roasted liquorice, 20 parts of julibrissin bark, 10 parts of scutellaria, 12 parts of poria, 10 parts of pinellia, 10 parts of acanthopanax, 10 parts of forsythia, 10 parts of codonopsis, 5 parts of aucklandia, 5 parts of bezoar, and 5 parts of musk; the temperature of water in steps S2 and S3 is 40°.
[0031] like Figure 1 As shown, clinical trial results:
[0032] 1. Clinical data
[0033] 84 patients with depression of liver depression and qi stagnation type from outpatient clinics and wards, all of whom met the syndrome differentiation criteria of liver depression and qi stagnation in traditional Chinese medicine, aged between 13 and 35 years, with a disease course of 0.5 to 8 years. They were randomly divided into 2 groups: 42 cases in the treatment group and 42 cases in the control group. There was no significant difference between the two groups in terms of gender, age, disease course, and Hamilton Depression 17-item (HAMD-17) score.
[0034] 2. Drug composition and usage
[0035] Concomitant medication: escitalopram,
[0036] Experimental group: escitalopram combined with the Chinese medicine composition of the present invention;
[0037] Control group: escitalopram monotherapy.
[0038] 3. Treatment options
[0039] 3.1 Entry and Exclusion Criteria
[0040] Inclusion criteria (all 6 items must be met)
[0041] ① Inpatients or outpatients aged 18-65 years (inclusive), regardless of gender;
[0042] ② Meet the diagnostic criteria for depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) or the diagnostic criteria in the International Classification of Diseases (ICD-10), either for the first episode or for a relapse;
[0043] ③ Meet the diagnostic criteria of liver depression and qi stagnation syndrome in traditional Chinese medicine. The diagnosis of liver depression and qi stagnation syndrome is as follows:
[0044] Main symptoms: depression, anxiety, chest and flank pain, abdominal discomfort
[0045] Secondary symptoms: irritability, nervousness, fear, sighing, poor appetite, abdominal distension, discomfort in the throat, irregular menstruation in women, abnormal bowel movements
[0046] Tongue and pulse: pale red tongue, thin white tongue, stringy pulse
[0047] A diagnosis can be made only if at least two of the main and secondary symptoms are met (tongue and pulse are not included in the entry);
[0048] ④Hamilton Depression Rating Scale (HAMD-17) score > 17 during the screening and baseline periods;
[0049] ⑤ Primary school education or above, able to understand the research content;
[0050] ⑥ I understand and voluntarily participate in this study and sign the informed consent form.
[0051] Exclusion criteria (if any one of the criteria is met, the criteria will be excluded)
[0052] ① Currently or previously suffered from other major mental disorders other than major depressive disorder in accordance with DSM-5 or ICD-10, such as neurodevelopmental disorders, neurocognitive disorders, schizophrenia and other psychotic disorders, bipolar disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, alcohol (or drug) dependence or abuse, personality disorder, etc.;
[0053] ② Depressive episodes secondary to organic mental disorders caused by certain systemic diseases or certain nervous system diseases, such as depressive episodes caused by hypothyroidism;
[0054] ③ Patients with severe or unstable cardiovascular, respiratory, liver, kidney, endocrine, blood system or other system diseases who are considered by the researchers to be unsuitable for inclusion in this study;
[0055] ④ Pregnant or lactating women, or women of childbearing age with positive results of human chorionic gonadotropin (HCG) / urine HCG test during the screening period; or men with reproductive potential or women of childbearing age who are unable to take effective contraceptive measures during the trial; or planning to conceive (pregnant) within 3 months after the start of the trial;
[0056] ⑤ Meet other TCM syndrome types, especially liver-kidney yin deficiency syndrome, liver depression transforming into fire syndrome and other syndromes;
[0057] ⑥ The researcher considers the patient unsuitable to participate in this study due to other reasons.
[0058] 3.2 Intervention measures
[0059] Treatment duration: Both groups received an 8-week intervention.
[0060] 3.3 Concomitant medication and treatment:
[0061] 3.3.1 Prohibited treatments and drugs
[0062] 1) Electroconvulsive therapy and repetitive transcranial magnetic stimulation are prohibited during the study;
[0063] 2) Other Chinese patent medicines for the treatment of depression;
[0064] 3) vasoactive substances such as adrenaline, norepinephrine, and dopamine;
[0065] 4) Acupuncture, moxibustion, cupping and other traditional Chinese medicine therapies;
[0066] 5) Drugs for the treatment of central nervous system diseases such as anti-Parkinson's drugs, anti-dementia drugs, cerebral vasodilators, etc.;
[0067] 6) Systematic psychotherapy is prohibited during the study.
[0068] 3.3.2 Permitted concomitant treatment
[0069] 1) People with severe insomnia can use sedative hypnotic drugs at night;
[0070] 2) Do not use anti-Parkinson's drugs preventively. If EPS occurs, trihexyphenidyl can be used in combination, with a dose of ≤10 mg / d; if acute dystonia occurs, scopolamine 0.3 mg can be injected intramuscularly once if necessary;
[0071] 3) Avoid using medications for insomnia, EPS, acute dystonia, excitement, or agitation within 8 hours before the scale assessment;
[0072] 4) If the patient has a general physical disease, symptomatic treatment may be given; for long-term medication, it is recommended that the type and dosage of medication remain unchanged during the study. If the condition is serious, the medication must be discontinued.
[0073] 4. Observation indicators and follow-up plan
[0074] 4.1 General Information
[0075] The patients' gender, age, course of depression, medication status, history of physical illness, family history, smoking, drinking history, diet, sleep and living habits were investigated.
[0076] 4.2 Scale Assessment
[0077] Other assessment scales: Hamilton Depression Rating Scale (HAMD-17) score, which is assessed by personnel who have received special training in psychological scales, and different personnel are tested for consistency.
[0078] Scale assessment time: The relevant scale scores were followed up and evaluated at baseline, the 4th week, and the 8th week.
[0079] 5. Efficacy evaluation
[0080] 5.1 Clinical effect evaluation
[0081] HAMD-17 score.
[0082] 5.2 Safety indicators: vital signs, physical examination, routine blood test, routine urine test, liver and kidney function test and electrocardiogram (ECG), adverse events and serious adverse events records.
[0083] 6. Statistical methods
[0084] All data were analyzed using SPSS 20.0 software package. Descriptive statistics were used for general data. The chi-square test was used. The normal distribution of measurement data was tested by the ks method, and the variance homogeneity test was tested by the Levene method. If the measurement data conformed to the normal distribution and the variance was homogeneous, the paired sample t test was used for intra-group comparison, and the independent sample t test or one-way analysis of variance was used for inter-group comparison.
[0085] 7. Results
[0086] General information: There was no statistically significant difference in age, education level, disease duration, HAMD score, and escitalopram dosage between the two groups at baseline (see Table 1).
[0087] Table 1 General information of patients
[0088]
[0089] Comparison of clinical efficacy between the treatment group and the control group: The main effect of the subject group was not significant (F=0.076, P=0.787), and the main effect of time was significant (F=9.519, P=0.001), that is, both groups showed improvement over time, but after simple effect analysis, it was found that the difference between the two groups was significant at the end of the 8th week (P<0.001), that is, the treatment group improved better. See Table 2.
[0090] Table 2 Clinical efficacy of the study group and the control group
[0091]
[0092] The above clinical trials show that the present invention is aimed at patients with depression of the liver depression and qi stagnation syndrome type, and the treatment is mainly based on drugs that dissipate heat and enter the liver to regulate qi, supplemented by products that nourish the blood and soften the liver, promote blood circulation and harmonize the stomach, soothe the liver and nourish the liver, regulate qi and regulate blood, regulate the liver and strengthen the spleen and harmonize the stomach, sort out the stagnation of qi, regulate qi, and improve the mental symptoms of patients with depression. This has been verified in a large sample population.
[0093] The changes in the inflammatory factors in the treatment group and the control group before and after treatment show that the present invention can effectively reduce inflammation. See Table 3.
[0094] Table 3 Verification changes between the study group and the control group
[0095]
[0096] The present invention can effectively relieve the symptoms of depression and other symptoms of patients with depression due to liver depression and qi stagnation syndrome, and the combined use effect with western medicine is significantly better than the effect of western medicine alone. Therefore, the composition provided by the present invention has the potential to be developed into a drug that can relieve the symptoms of patients with depression, reduce the inflammatory response of the patient's body, and improve the immunity of patients with depression.
[0097] It is worth noting that, based on the above structural design, in order to solve the same technical problem, even if some insubstantial changes or modifications are made to the present invention, the essence of the technical solution adopted is still the same as the present invention, so it should also be within the protection scope of the present invention.
Claims
1. A Chinese medicine composition for relieving depression of liver depression and qi stagnation syndrome, characterized in that: It is composed of the following components: dried tangerine peel, bupleurum, chuanxiong, cyperus rotundus, fructus aurantii, white peony root, roasted licorice, julibrissin bark, scutellaria baicalensis, poria, pinellia ternata, acanthopanax senticosus, forsythia suspensa, codonopsis pilosula, costusroot, bezoar and musk.
2. A Chinese medicine composition for relieving depression of liver depression and qi stagnation syndrome according to claim 1, characterized in that: 5-10 parts of dried tangerine peel, 8-10 parts of bupleurum, 5-10 parts of chuanxiong, 7-10 parts of cyperus, 5-10 parts of fructus aurantii, 5-10 parts of white peony root, 5-10 parts of roasted liquorice, 15-20 parts of julibrissin bark, 5-10 parts of scutellaria, 7-12 parts of poria, 5-10 parts of pinellia, 5-10 parts of acanthopanax, 5-10 parts of forsythia, 5-10 parts of codonopsis, 2-5 parts of aucklandia, 2-5 parts of bezoar, and 2-5 parts of musk.
3. A Chinese medicine composition for relieving depression of liver depression and qi stagnation syndrome according to claim 1, characterized in that: Tangerine peel 8 parts, bupleurum 9 parts, chuanxiong 8 parts, cyperus rotundus 8 parts, fructus aurantii 8 parts, white peony root 8 parts, roasted liquorice 7 parts, julibrissin bark 18 parts, scutellaria 8 parts, poria 9 parts, pinellia 7 parts, acanthopanax 8 parts, forsythia 7 parts, codonopsis pilosula 7 parts, aucklandia 3 parts, bezoar 3 parts, musk 3 parts.
4. A Chinese medicine composition for relieving depression of liver depression and qi stagnation syndrome according to claim 1, characterized in that: The preparation method thereof comprises: S1, take parts by weight of dried tangerine peel, bupleurum, chuanxiong, cyperus, fructus aurantii, white peony root, licorice root, julibrissin, scutellaria, tuckahoe, pinellia, acanthopanax, forsythia, and codonopsis, wash them in clean water to remove sediment and impurities, and then filter them as a mixture for later use; take parts by weight of Tibetan wood root, bezoar, and musk, grind them into powder and mix them for later use; S2, add twice the weight of water to the mixture, the water temperature is 30-40°C, boil over high heat for 60-150 minutes, filter and take the juice for later use; S3, add 1.5 times the weight of water to the juice, the water temperature is 30-40°C, boil over high heat and then simmer over low heat to make a concentrated solution with one quarter of the total amount of original juice and water; S4, after the mixed concentrated liquid is dried, a solid is obtained, the solid is ground into powder, dextrin and the powder mixture of step S1 are added, mixed, sterilized, bagged and packaged.
Citation Information
Patent Citations
A pharmaceutical composition for treating mental depression
CN101530599A
Traditional Chinese medicine composition for treating depression
CN102973758A
Traditional Chinese medicinal mixture for treating depression
CN106421050A
Traditional Chinese medicine composition for treating chronic digestive disease associated with anxiety and depression status
CN109045201A
Supplemented bupleurum liver-coursing powder based on simultaneous treatment of heart, liver and spleen
CN109223937A
